{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Transthyretin+Amyloidosis+With+Cardiomyopathy&page=2", "query": { "condition": "Transthyretin Amyloidosis With Cardiomyopathy", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Transthyretin+Amyloidosis+With+Cardiomyopathy&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-26T21:39:53.104Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05505838", "title": "Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis With Cardiomyopathy", "overall_status": "NO_LONGER_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Transthyretin-mediated Amyloidosis With Cardiomyopathy", "ATTR Amyloidosis With Cardiomyopathy" ], "interventions": [ { "name": "Patisiran", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alnylam Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2024-02-16", "last_synced_at": "2026-06-26T21:39:53.104Z", "location_count": 20, "location_summary": "Phoenix, Arizona • Los Angeles, California • San Diego, California + 17 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05505838" }, { "nct_id": "NCT01994889", "title": "Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Transthyretin (TTR) Amyloid Cardiomyopathy" ], "interventions": [ { "name": "Tafamidis", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 441, "start_date": "2013-12-09", "completion_date": "2018-02-07", "has_results": true, "last_update_posted_date": "2019-04-24", "last_synced_at": "2026-06-26T21:39:53.104Z", "location_count": 50, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 24 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01994889" }, { "nct_id": "NCT02319005", "title": "ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)", "Amyloidosis, Hereditary", "Amyloid Neuropathies, Familial", "Amyloid Neuropathies", "Amyloidosis, Hereditary, Transthyretin-Related", "Familial Transthyretin Cardiac Amyloidosis" ], "interventions": [ { "name": "Revusiran (ALN-TTRSC)", "type": "DRUG" }, { "name": "Sterile Normal Saline (0.9% NaCl)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alnylam Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 206, "start_date": "2014-12", "completion_date": "2017-03-30", "has_results": true, "last_update_posted_date": "2018-07-18", "last_synced_at": "2026-06-26T21:39:53.104Z", "location_count": 41, "location_summary": "Bakersfield, California • Beverly Hills, California • La Mesa, California + 30 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02319005" }, { "nct_id": "NCT03458130", "title": "Study of AG10 in Amyloid Cardiomyopathy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Familial ATTR-CM (ATTRm-CM, or FAC)", "Wild-type ATTR-CM (ATTRwt-CM)" ], "interventions": [ { "name": "AG10", "type": "DRUG" }, { "name": "Placebo Oral Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eidos Therapeutics, a BridgeBio company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 49, "start_date": "2018-04-27", "completion_date": "2018-10-05", "has_results": true, "last_update_posted_date": "2022-11-16", "last_synced_at": "2026-06-26T21:39:53.104Z", "location_count": 13, "location_summary": "Beverly Hills, California • Palo Alto, California • San Francisco, California + 9 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03458130" }, { "nct_id": "NCT07052903", "title": "TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Transthyretin Amyloidosis With Cardiomyopathy" ], "interventions": [ { "name": "Nucresiran", "type": "DRUG" }, { "name": "Sterile Normal Saline (0.9% NaCl)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alnylam Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 1250, "start_date": "2025-07-02", "completion_date": "2032-11-30", "has_results": false, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-06-26T21:39:53.104Z", "location_count": 39, "location_summary": "La Jolla, California • Stanford, California • Norwich, Connecticut + 32 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Norwich", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Brandon", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07052903" }, { "nct_id": "NCT00935012", "title": "Safety And Efficacy Evaluation Of Fx-1006a In Patients With V122i Or Wild-Type Transthyretin (TTR) Amyloid Cardiomyopathy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "ATTR-CM", "TTR-CM" ], "interventions": [ { "name": "tafamidis", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 31, "start_date": "2009-09-30", "completion_date": "2019-11-20", "has_results": true, "last_update_posted_date": "2021-01-05", "last_synced_at": "2026-06-26T21:39:53.104Z", "location_count": 7, "location_summary": "Atlanta, Georgia • Chicago, Illinois • Baltimore, Maryland + 2 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00935012" }, { "nct_id": "NCT04843020", "title": "ION-682884 in Patients With TTR Amyloid Cardiomyopathy", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Transthyretin Amyloid Cardiopathy" ], "interventions": [ { "name": "ION 682884", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "65 Years to 85 Years" }, "enrollment_count": 0, "start_date": "2021-06-01", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2026-02-20", "last_synced_at": "2026-06-26T21:39:53.104Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04843020" }, { "nct_id": "NCT07358078", "title": "DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Transthyretin Amyloidosis With Cardiomyopathy" ], "interventions": [], "intervention_types": [], "sponsor": "Alnylam Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2000, "start_date": "2026-01-09", "completion_date": "2030-10-23", "has_results": false, "last_update_posted_date": "2026-04-24", "last_synced_at": "2026-06-26T21:39:53.104Z", "location_count": 4, "location_summary": "Naples, Florida • Boston, Massachusetts • New Brunswick, New Jersey + 1 more", "locations": [ { "city": "Naples", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT07358078" }, { "nct_id": "NCT03997383", "title": "APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Transthyretin Amyloidosis (ATTR) With Cardiomyopathy" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Patisiran", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alnylam Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 360, "start_date": "2019-09-04", "completion_date": "2025-12-24", "has_results": true, "last_update_posted_date": "2026-04-20", "last_synced_at": "2026-06-26T21:39:53.104Z", "location_count": 19, "location_summary": "Los Angeles, California • Chicago, Illinois • Skokie, Illinois + 14 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Skokie", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03997383" }, { "nct_id": "NCT06029452", "title": "A Retrospective Validation Study To Identify Chart-Based Clinical Diagnosis Of Wild-Type Transthyretin Amyloid Cardiomyopathy (Attrwt-CM) And Non-Amyloid Heart Failure Among Patients With Heart Failure (HF).", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "ATTR-CM" ], "interventions": [ { "name": "Machine learning algorithm", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 558, "start_date": "2023-09-01", "completion_date": "2023-11-14", "has_results": true, "last_update_posted_date": "2025-01-03", "last_synced_at": "2026-06-26T21:39:53.104Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06029452" } ] }